Corporate Communications:
Dr. Lise Hébert
(450) 680-4500
Toll free (877) 680-4500
If you need additional assistance or information regarding the company, please
send an Email to:
webinfo@neurochem.com.
November 22, 2005
- Neurochem enrolls first patient in Phase III clinical trial for Alzheimer's disease in Europe
Study on schedule
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that the first patient in its European Phase III clinical trial
on Alzhemed™ (3-amino-1-propanesulfonic acid, 3APS), has been...
(learn more by clicking here)
November 17, 2005
- Neurochem closes sale and leaseback transaction for Laval facilities
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that it has closed the sale and leaseback transaction for its
campus located in Laval, Quebec, including its head office and...
(learn more by clicking here)
November 8, 2005
- Neurochem reports results for third quarter of fiscal 2005
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) reported results for the third quarter ended September 30, 2005. The
Company reported a net loss of $21.1 million ($0.58 per share) for the...
(learn more by clicking here)
November 8, 2005
- Neurochem announces sale and leaseback transaction for Laval facilities - sale price of C$32 million
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that it has entered into a sale and leaseback transaction
with an affiliate of Alexandria Real Estate Equities, Inc. (NYSE:ARE). The...
(learn more by clicking here)
November 7, 2005
- Neurochem to report on third quarter of fiscal 2005
Neurochem will host a conference call Tuesday, November 8, 2005, at 4:30 P.M. ET
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announced that on Tuesday, November 8, it will release its results for
the third quarter of fiscal 2005 ended September 30...
(learn more by clicking here)
November 3, 2005
- Neurochem to present at CIBC World Markets Sixteenth Annual Healthcare Conference
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that on Monday, November 7, 2005, Dr. Francesco Bellini,
Chairman, President and CEO, will present Neurochem's overall...
(learn more by clicking here)
October 5, 2005
- Neurochem receives third positive recommendation from Independent Safety Review Board to continue
Phase III clinical trial for Alzhemed™
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that its Independent Safety Review Board (ISRB) has issued a
third recommendation to continue the Company's North...
(learn more by clicking here)
September 26, 2005
- Neurochem to present at 2005 UBS Global Life Sciences Conference in New York City
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that on Wednesday, September 28, 2005, Dr. Francesco Bellini,
Neurochem's Chairman, President and CEO, will present the...
(learn more by clicking here)
September 13, 2005
- Neurochem announces launch of European Phase III clinical trial on Alzhemed™ for treatment of
Alzheimer's Disease
North American Phase III Clinical Trial on Alzhemed™ Fully Enrolled
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that it has launched its European Phase III clinical trial
on Alzhemed™, following an investigators' meeting attended by...
(learn more by clicking here)
August 22, 2005
- Neurochem initiates submission of NDA with the U.S. FDA for Fibrillex™ in AA Amyloidosis.
Ecublens (Switzerland) - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc.
(NASDAQ: NRMX; TSX: NRM), announced today that it has...
(learn more by clicking here)
August 10, 2005
- Neurochem reports results for second quarter of fiscal 2005.
Neurochem will host a conference call Thursday, August 11, 2005, at 8:30 A.M. ET.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announced results for the second quarter ended June 30, 2005. The
Company reported a net loss of $18.7 million ($0.54 per share) for the...
(learn more by clicking here)
July 25, 2005
- Neurochem Inc. announces exercise of warrant by Picchio Pharma Inc.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that a subsidiary of Picchio Pharma Inc. (Picchio Pharma)
has exercised a warrant previously issued under a July 2002 private...
(learn more by clicking here)
July 5, 2005
- Neurochem completes patient recruitment for North American Phase III clinical trial for Alzhemed™
Milestone on Schedule
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today the completion of recruitment of the 950 patients with mild-to-
moderate Alzheimer's Disease (AD) for its North American...
(learn more by clicking here)
June 30, 2005
- Neurochem announces FDA agrees to file and review NDA for Fibrillex™
Ecublens (Switzerland) - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc.
(NASDAQ: NRMX; TSX: NRM), today announced that the...
(learn more by clicking here)
June 13, 2005
- Neurochem receives second positive recommendation from Independent Safety Review Board to continue Phase III
clinical trial for Alzhemed™
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that its Independent Safety Review Board (ISRB) has issued
a second recommendation to continue the Company's North...
(learn more by clicking here)
June 9, 2005
- New Fibrillex™ data presented at the meeting of the European League Against Rheumatism (EULAR).
Vienna, Austria - Further analyses of the results of Neurochem's Phase II/III clinical study for Fibrillex™, an
investigational product candidate for the treatment of Amyloid A (AA) Amyloidosis, were...
(learn more by clicking here)
June 5, 2005
- New Fibrillex™ Data Presented at the European Renal Association-European Dialysis and Transplant
Association Meeting.
Istanbul, Turkey - Further analyses of the results of Neurochem's Phase II/III clinical study for Fibrillex(TM), an
investigational product candidate for the treatment of Amyloid A (AA) Amyloidosis, were...
(learn more by clicking here)
May 19, 2005
- Neurochem to present at UBS Global Pharmaceuticals Conference and at Fourth Annual Needham Biotechnology Conference.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that on May 24, 2005, Francesco Bellini, PhD, Chairman,
President and CEO, will present Neurochem's overall strategy...
(learn more by clicking here)
May 12, 2005
- At Annual and Special Meeting of Shareholders
Neurochem highlights the advancement of its drug development program as priority - issues first quarter results.
At the annual and special meeting of shareholders, Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) highlighted the recent
advances of its investigational product candidates Fibrillex™ and...
(learn more by clicking here)
April 26, 2005
- Neurochem receives positive recommendation from Independant Safety Review Board to continue
phase III clinical trial for Alzhemed™.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that its Independent Safety Review Board (ISRB) has issued a
recommendation to continue the Company's North American...
(learn more by clicking here)
April 18, 2005
- Neurochem announces preliminary results of Phase II/III clinical study for Fibrillex™.
Plans meeting with FDA to present results.
Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM),
announced today preliminary results from the Phase II/III clinical...
(learn more by clicking here)
April 8, 2005
- Neurochem unblinds the Phase II/III Clinical Study for Fibrillex™ in the treatment of
AA Amyloidosis.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that it has unblinded the Phase II/III clinical study for its
investigational product candidate, 1,3-propanedisulfonate...
(learn more by clicking here)
March 31, 2005
- Neurochem to present at CIBC World Markets Annual Biotechnology & Specialty
Pharmaceuticals Conference.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that on Monday, April 4, 2005, Francesco Bellini, PhD,
Chairman, President and CEO, will present Neurochem's overall strategy...
(learn more by clicking here)
March 4, 2005
- Neurochem Inc. prices public offering of 4 million common shares for gross proceeds of US$ 61.2 million.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that its registration statement has become effective under
the U.S. Securities Act of 1933 and that it has obtained a receipt for a final...
(learn more by clicking here)
March 9, 2005
- Neurochem Inc. completes public offering of 4 million common shares for gross proceeds of US$61.2 million.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that it has completed its formerly announced public offering
of 4 million common shares. The common shares were sold in the...
(learn more by clicking here)
March 4, 2005
- Neurochem Inc. prices public offering of 4 million common shares for gross proceeds of US$ 61.2 million.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that its registration statement has become effective under
the U.S. Securities Act of 1933 and that it has obtained a receipt for a final...
(learn more by clicking here)
February 23, 2005
- Neurochem Inc. files preliminary prospectus with Canadian and US Securities authorities for an offering
of four million common shares.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that it has filed a short form preliminary prospectus with
the Canadian securities regulators and a registration statement with...
(learn more by clicking here)
February 22, 2005
- Neurochem reports results for fourth quarter of fiscal 2004.
Neurochem will host a conference call Tuesday, Feb. 22, at 4:30 P.M. ET.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) and subsidiaries ("the Company") today announced consolidated
results for the fourth quarter and fiscal year ended Dec. 31, 2004. The...
(learn more by clicking here)
January 20, 2005
- Francesco Bellini renews mandate for three-years as Chairman, President and CEO of Neurochem.
Neurochem Inc. announces senior management appointments and reassignment of responsibilities.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) today announced the renewed commitment by Francesco Bellini, Chairman and
CEO, to remain with the Company in an executive capacity for...
(learn more by clicking here)
|
2008
Archives 2004
